French drugmaker Ipsen’s Cabometyx (cabozantinib) has been recommended by the National Institute for Health and…
Latest news
A partnership between two UK digital health companies – Brainomix and Visionable – aims to…
Clovis Oncology has said it may not have enough cash to fund continuing operations beyond…
Five months after giving up on its lead drug Betalutin for follicular lymphoma, Nordic Nanovector…
- Pharma News
‘Healthcare shouldn’t be about treatment’: are diagnostics the answer to ending disease and virus outbreaks?
In a perfect world, everyone would have equal access to healthcare. The health services some…
Patients have a unique first-hand insight into their condition, which can be a valuable asset…
AstraZeneca has moved a step closer to bringing a first-in-class drug to market in the…
A £16 million Series A financing – led by Omega Funds – has been announced…
It goes without saying that The Economist’s 8th Annual World Cancer Series congress was well-attended…
ADC Therapeutics has said it will not seek accelerated approval of its Hodgkin lymphoma drug…
GSK has revealed updated results from its phase 2b trial of its antisense drug for…
Sanofi has tapped into the artificial intelligence expertise of Chinese biotech Insilico Medicine with a…
If we look back just 70 years, the prognosis for patients with haemophilia was remarkably…
Australian digital health Respiri has started to roll out its digital remote patient monitoring (RPM)…
For the first time, patients in England with triple-negative breast cancer (TNBC) will be able…
People whose blood pressure remains stubbornly high despite current drug treatment and are at increased…
After years of preparation, Eli Lilly is on the brink of launching a fully connected…
Due to the pandemic, decentralised trial solutions made the shift from an emerging trend to…
Ask nearly any pharma company these days if they’re patient-centric, and you’ll probably get an…
Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a…
GSK has great expectations for its BCMA-directed cancer drug Blenrep, but a failed phase 3…
While investment in NASH has waned in the context of rigid histological endpoints and clinical…
SAE Media Group reports: Mitchell de Long, Vice President, Chemistry from Aerie Pharmaceuticals and Naj…
In this new segment from pharmaphorum, we collect the most significant hirings, firings, and recruitment…
Draft guidance in the UK has provisionally recommended that digital cognitive behavioural therapy (CBT) apps…
Blood cells grown in a laboratory have been given to people for the first time…
The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is…
Eli Lilly plans for a new biopharmaceutical manufacturing facility in Ireland that will be used…
AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug…
The value of data has never been greater in healthcare. With greater digital engagement and…
BioNTech and Pfizer have announced that they are initiating a phase 1 study to evaluate…
When long-serving Johnson & Johnson R&D chief Paul Stoffels cut short his retirement to take…
Boehringer Ingelheim has appointed Lykke Hinsch Gylvin as its new head of medicine and chief…
To address the supply chain vulnerabilities of the pharma industry, an innovative, collaborative blockchain-based system…
Consumer and health organisations in the UK have written to the Trade Secretary Kemi Badenoch,…
The hope that nerve growth factor (NGF) inhibitors could be an alternative to opioid for…
In an encouraging development for the fight against antimicrobial resistance (AMR), GSK’s novel antibiotic gepotidacin…
Alkermes has said it is considering a spin-out of its cancer business into an independent,…
At Frontiers Health 2022, pharmaphorum Editor in Chief Jonah Comstock sat down with Matthew Holt,…
In this episode of the pharmaphorum podcast, host Jonah Comstock taps XIL Health’s Susan Lang…
The psychedelic compound in magic mushrooms – psilocybin – can improve the symptoms of severe…
December marks the one year anniversary of the U.S. Food and Drug Administration’s (FDA) draft…
Thursday 3rd November marks the second day of Anthropy 2022 at the Eden Project on…
CVS Health and Walgreens have become the first two US pharmacy chains to agree a…
Johnson & Johnson’s $16.6 billion takeover offer for cardiac pump manufacturer Abiomed looks set to…
In its first set of quarterly results since it separated from its consumer health business,…
Australia’s CSL is the latest vaccines company to buy into the mRNA category, tapping US…
One of the highlights of Eli Lilly’s third-quarter results was the rapid uptake of new…
Wednesday 2nd November heralds the start of Anthropy 2022 at The Eden Project. With pharmaphorum…
Citeline and Norstella have completed a merger, first announced in June, to create one of…